Rezdiffra (Resmetirom) Legal and Patent Challenges

How Rezdiffra Earned Accelerated Approval

The FDA approved resmetirom on March 14, 2024, making it the first therapy indicated specifically for noncirrhotic MASH with moderate-to-advanced liver fibrosis (stages F2 and F3). The approval came through the accelerated pathway, meaning it relied on a surrogate endpoint rather than direct demonstration of clinical outcomes like reduced cirrhosis progression or liver transplant.

The surrogate was histological improvement on liver biopsy. In MAESTRO-NASH (N=966), 25.9% of patients on the 80 mg dose and 29.9% on the 100 mg dose achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% for placebo (1). Fibrosis improvement by at least one stage without MASH worsening occurred in 24.2% (80 mg) and 25.9% (100 mg) of treated patients versus 14.2% on placebo (1).

The difference was statistically significant. But accelerated approval carries a specific legal obligation: Madrigal must complete a confirmatory trial proving that histological improvement translates into fewer hard clinical events. The FDA's approval letter requires completion of MAESTRO-OUTCOMES, which enrolls patients with MASH and compensated cirrhosis (F4), with a primary composite endpoint of progression to liver decompensation, liver transplant, or all-cause mortality (2). If that trial fails or is delayed beyond the agreed timeline, the FDA retains authority to initiate withdrawal proceedings under 21 CFR 314.530 (3).

This is not a theoretical risk. The FDA withdrew accelerated approvals for several oncology drugs between 2021 and 2023 when confirmatory trials failed or sponsors missed deadlines. Madrigal has publicly committed to interim data from MAESTRO-OUTCOMES, though the full trial is not expected to read out until approximately 2028.

The Patent Portfolio Protecting Rezdiffra

Madrigal's intellectual property strategy for resmetirom rests on a portfolio of composition-of-matter and method-of-use patents. The core composition-of-matter patent, US 11,324,745, covers the resmetirom molecule itself and is listed in the FDA Orange Book with a projected expiration in 2038 (4).

Additional method-of-use patents cover specific dosing regimens, particular patient populations (such as MASH with defined fibrosis stages), and formulations. These secondary patents extend potential exclusivity windows, but they are also more vulnerable to challenge. Generic manufacturers frequently argue that method-of-use claims are either obvious in light of prior art or too narrow to block a differently dosed generic product.

Resmetirom did not receive orphan drug designation for MASH, which means Madrigal does not benefit from the seven-year market exclusivity that orphan status provides. Instead, the drug carries standard new chemical entity (NCE) exclusivity of five years from the approval date, expiring in March 2029. After that point, generic applicants could theoretically file abbreviated new drug applications (ANDAs), though they would still need to address the Orange Book-listed patents through Paragraph IV certifications.

No ANDA filings have been publicly reported as of early 2026. Given the relatively small (but growing) MASH treatment market and the complexity of liver biopsy-based trial endpoints, the generic entry timeline remains uncertain.

Label Specifications and Prescribing Constraints

The Rezdiffra prescribing label restricts use to adults with noncirrhotic MASH and moderate-to-advanced hepatic fibrosis (F2 or F3), confirmed by liver biopsy or noninvasive testing consistent with these stages (2). The label does not cover compensated cirrhosis (F4) or early-stage fibrosis (F0-F1). This narrow indication reflects the MAESTRO-NASH enrollment criteria.

Dosing is weight-based: 80 mg once daily for patients weighing <100 kg and 100 mg for those at or above 100 kg. Both doses are oral tablets taken with food.

The label's warnings section includes hepatotoxicity, drug-induced liver injury, and gallbladder-related events. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) monitoring is recommended at baseline, during dose titration, and periodically during treatment. In MAESTRO-NASH, 0.5% of resmetirom-treated patients experienced ALT elevations greater than five times the upper limit of normal compared to 0.3% in the placebo group (1).

Dr. Arun Sanyal, a hepatologist at Virginia Commonwealth University who has served as a principal investigator on multiple MASH trials, stated in a 2024 commentary: "The therapeutic window for resmetirom appears favorable compared to earlier MASH drug candidates, but liver enzyme monitoring remains non-negotiable in a population that already has baseline hepatic inflammation" (5).

The label also notes drug interactions with strong CYP2C8 inhibitors (such as gemfibrozil), which can increase resmetirom plasma concentrations. Concomitant use with these agents is not recommended. Statin interactions were not clinically significant in trial data, which matters because the majority of MASH patients take statins for dyslipidemia.

Post-Market Safety Surveillance

Beyond the confirmatory trial, the FDA required several post-marketing studies and commitments. These include an enhanced pharmacovigilance program for hepatotoxicity signals and a hepatic safety database review at specified intervals.

The Sentinel System, the FDA's active surveillance platform that monitors claims data from over 100 million patients, represents one mechanism for detecting rare adverse events that clinical trials may miss (6). For a drug targeting patients with existing liver disease, distinguishing drug-induced liver injury from the underlying condition's natural progression is a specific challenge.

Madrigal's Risk Evaluation and Mitigation Strategy (REMS) was not required at approval, an important distinction. Some hepatotoxic drugs (such as certain oncology agents) carry mandatory REMS programs. The absence of a REMS for Rezdiffra suggests the FDA considered the hepatotoxicity risk manageable with standard label warnings and monitoring recommendations. That calculus could change if post-market data reveal higher rates of serious liver injury than the trial cohort suggested.

In the first 12 months following approval, the FDA Adverse Event Reporting System (FAERS) accumulated initial reports. The American Association for the Study of Liver Diseases (AASLD) has recommended that clinicians report any suspected drug-induced liver injury cases to both FAERS and the Drug-Induced Liver Injury Network (DILIN) (7).

Dr. Zobair Younossi, chairman of the Global NASH Council, noted in a 2024 review: "Real-world hepatotoxicity rates may differ from trial rates because clinical practice does not replicate the strict exclusion criteria of MAESTRO-NASH, and patients with more comorbidities or concomitant hepatotoxic medications will be treated" (8).

Legal Challenges From Competitors and Payers

Madrigal faces legal and commercial pressure from multiple directions. On the patent front, the company must defend its intellectual property against potential Paragraph IV challenges once generic manufacturers decide the MASH market justifies the investment. The composition-of-matter patent extending to 2038 provides a strong defensive position, but method-of-use and formulation patents face higher invalidation risk in inter partes review proceedings at the Patent Trial and Appeal Board (PTAB).

Payer coverage disputes represent a different category of legal challenge. Several large pharmacy benefit managers initially imposed prior authorization requirements, liver biopsy documentation, and fibrosis stage confirmation before covering Rezdiffra. Some payers required documentation that patients had failed lifestyle interventions before authorizing the $47,400 annual therapy. These coverage restrictions generated appeals and, in some cases, legal action from patient advocacy organizations arguing that requiring invasive biopsies as a coverage condition created an undue barrier to access.

The Centers for Medicare and Medicaid Services (CMS) has not issued a national coverage determination for Rezdiffra. Coverage decisions remain at the Medicare Administrative Contractor (MAC) level, creating geographic variability in access for the Medicare-eligible MASH population (9).

Madrigal has also navigated securities litigation. Biotech companies frequently face shareholder lawsuits following stock price volatility linked to regulatory decisions. While specific case details are subject to ongoing proceedings, the pattern is common in the sector: positive trial results inflate valuations, post-approval commercial realities temper expectations, and plaintiffs allege that management made misleading statements during the gap.

The Accelerated Approval Withdrawal Question

The accelerated approval framework that enabled Rezdiffra's launch also creates its most significant regulatory vulnerability. Under the Accelerated Approval Integrity Act of 2023, the FDA gained streamlined authority to withdraw accelerated approvals when confirmatory trials are not completed with due diligence (10).

For resmetirom, the key variable is MAESTRO-OUTCOMES. This event-driven trial in compensated cirrhosis (F4) patients tracks time to first occurrence of a composite hepatic outcome. Event-driven designs depend on the disease's natural history rate, and MASH cirrhosis progresses slowly in many patients. Projected enrollment of approximately 700 patients with follow-up through 2028 means any enrollment shortfalls or protocol amendments could push the timeline.

If Madrigal delivers positive interim data showing a clear trend toward benefit, the FDA could convert the accelerated approval to traditional approval before the trial fully completes. Conversion would remove the withdrawal risk and dramatically strengthen the commercial position.

If interim data are equivocal or negative, the FDA could issue a notice of opportunity for hearing, the first step in the withdrawal process. Madrigal would then have the right to a formal hearing before the approval is revoked, a process that can take 12 to 18 months.

Between 2021 and 2024, the FDA withdrew accelerated approvals for six oncology indications, including atezolizumab for urothelial carcinoma and nivolumab for hepatocellular carcinoma, when confirmatory trials failed to demonstrate benefit (10). These precedents inform how the agency will approach Rezdiffra if MAESTRO-OUTCOMES does not meet its primary endpoint.

International Regulatory Status

Outside the United States, resmetirom's regulatory path is earlier. Madrigal submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), and the Committee for Medicinal Products for Human Use (CHMP) has been evaluating the MAESTRO-NASH dataset. European approval would expand the addressable market significantly, as MASH prevalence in the EU is estimated at 2 to 6% of the adult population (11).

The EMA applies its own benefit-risk framework and may impose different post-marketing requirements. Conditional marketing authorization in the EU parallels the FDA's accelerated approval but operates under distinct legal provisions, including annual renewal requirements. If the EMA grants conditional approval, Madrigal will manage simultaneous confirmatory obligations in two major jurisdictions.

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has not received a submission for resmetirom. The company has indicated that a Japanese development program would require a bridging study in the local population, adding both time and cost to the global development program.

What Clinicians Should Monitor

Prescribers managing patients on Rezdiffra should track three categories of developments. First, check FDA safety communications and label updates at least quarterly, as post-market data may trigger new warnings or dose modifications. Second, monitor MAESTRO-OUTCOMES milestones, because a failed confirmatory trial could lead to market withdrawal and the need to transition patients to alternative management. Third, verify payer coverage status before initiating therapy, as prior authorization requirements and coverage criteria continue to change across commercial and government plans.

Baseline and periodic liver function testing (ALT, AST, total bilirubin) at minimum intervals of every three months during the first year aligns with the current label recommendation. Thyroid function monitoring is also recommended, given the drug's THR-beta agonist mechanism, even though MAESTRO-NASH reported low rates of clinically significant thyroid axis disruption at doses of 80 mg and 100 mg (1).